USE OF COLLOIDS OF CHROMIC [P-32] PHOSPHATE IN TREATMENT OF SOLID TUMORS

In order to evaluate the effectiveness of an intratumorally single dos e of chromic [P-32] phosphate for the treatment of solid tumors, studi es of bioelimination, biodistribution, and therapeutic action were car ried out. Only for comparative purposes were similar studies undertake n using a solution of sodium [P-32] orthophosphate-gelatin. Results sh ow that when sodium [P-32] orthophosphate-gelatin was intratumorally i njected, the percentage of total elimination, after 32 days of treatme nt, was equal to 85.90 +/- 8.70%, with a higher percentage in urine (6 4.50 +/- 13.70%) than in feces (21.40 +/- 4.50%). In biodistribution s tudies, the greater percentage was found in bone (15.54 +/- 2.21%), wh ereas only 2.51 +/- 0.39% remained in the tumor, When chromic [P-32] p hosphate was intratumorally injected, we found that the total eliminat ion was equal to 51.70 +/- 6.90%, with a higher amount in feces (32.70 +/- 4.80%) than in urine (19.00 +/- 3.60%). Biodistribution studies d emonstrated that 28.93 +/- 1.30% was still in the tumor and 19.01 +/- 1.30% of the injected activity was found in the liver. On the other ha nd, when therapeutic action was evaluated, no tumoral regression was o bserved. These results demonstrate that the colloid of chromic [P-32] phosphate cannot be used in the treatment of solid tumors as it mobili zes from the injection point, delivering a high dose to the entire org anism. Copyright (C) 1996 Elsevier Science Inc.